Competitive Process - Tumour Infiltrating Lymphocyte Therapy hubs for Melanoma
Details
- Buyer
- NHS England
- Published
- 16 May 2025
- Submission
- 1 July 2025
- Source
- uk:atamis:dhsc
Tender description
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential of many unwarranted side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to ITU.
Timeline
- Completed: Tender published16 May 2025Current notice
- Completed: Submission date1 July 2025
About the buyer
NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@nhs-england.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@nhs-england.gov |
Related topics
Topics related to Competitive Process - Tumour Infiltrating Lymphocyte Therapy hubs for Melanoma, ranked by notice volume.
- 6,447£32.8bn
Related buyers
Buyers similar to NHS England.
- 455£2.1bn
- 367£249.3m
- 358£15.0bn
- 293£2.8bn
- 263£19.7bn
- 258£901.0m
- 247£509.3m
- 203£1.0bn
- 140£895.5m
- 115£59.6m
Win more public sector contracts
Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.
